This clinical trial is focused on studying treatments for Chronic Hepatitis D Virus (HDV) Infection. The study will compare the effectiveness and safety of a combination therapy using two medications, Tobevibart and Elebsiran, against another medication called Bulevirtide. Tobevibart is a type of protein that acts as a monoclonal antibody, which means it is designed to target specific parts of the virus. Elebsiran is a nucleic acid-based treatment, which means it works at the genetic level to interfere with the virus’s ability to replicate. Bulevirtide is a protein-based treatment that is already used for managing HDV infection.
The purpose of this study is to evaluate how well the combination of Tobevibart and Elebsiran works compared to Bulevirtide in reducing the amount of virus in the body and to assess the safety of these treatments. Participants in the study will receive either the combination therapy or Bulevirtide and will be monitored over a period of time to see how their condition changes. The study will also look at how the treatments affect the liver and overall health of the participants.
Participants will receive the treatments through subcutaneous injections, which means the medication is injected under the skin. The study will take place over several weeks, with regular check-ups to monitor the participants’ health and the effectiveness of the treatments. The goal is to find out which treatment is more effective in managing Chronic Hepatitis D Virus (HDV) Infection and to ensure that the treatments are safe for the participants.
Belgium 
Bulgaria 
France 
Germany 
Italy 
Romania 
Spain 
The Netherlands 
